Zacks Research Issues Positive Outlook for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Analysts at Zacks Research raised their Q1 2025 earnings estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.88 per share for the quarter, up from their previous forecast of $0.87. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q2 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.30 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $6.00 EPS and FY2027 earnings at $7.39 EPS.

Other equities research analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark reaffirmed a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $62.89.

Halozyme Therapeutics Stock Up 1.9 %

NASDAQ:HALO traded up $1.16 during mid-day trading on Thursday, hitting $61.19. The stock had a trading volume of 1,098,414 shares, compared to its average volume of 1,443,747. Halozyme Therapeutics has a twelve month low of $40.19 and a twelve month high of $66.00. The stock has a 50-day simple moving average of $60.79 and a two-hundred day simple moving average of $55.39. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market capitalization of $7.56 billion, a PE ratio of 17.84, a PEG ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company's stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,697 shares of company stock valued at $1,558,052. Insiders own 2.40% of the company's stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently made changes to their positions in the company. Verdence Capital Advisors LLC raised its holdings in Halozyme Therapeutics by 2.8% during the first quarter. Verdence Capital Advisors LLC now owns 13,601 shares of the biopharmaceutical company's stock worth $868,000 after purchasing an additional 370 shares in the last quarter. James Investment Research Inc. raised its stake in shares of Halozyme Therapeutics by 27.8% during the 1st quarter. James Investment Research Inc. now owns 36,528 shares of the biopharmaceutical company's stock worth $2,331,000 after buying an additional 7,949 shares in the last quarter. Tectonic Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 26.7% in the 1st quarter. Tectonic Advisors LLC now owns 30,559 shares of the biopharmaceutical company's stock valued at $1,950,000 after buying an additional 6,438 shares during the period. Dakota Wealth Management purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $396,000. Finally, Edgestream Partners L.P. grew its holdings in Halozyme Therapeutics by 734.8% during the first quarter. Edgestream Partners L.P. now owns 135,403 shares of the biopharmaceutical company's stock worth $8,640,000 after acquiring an additional 119,183 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.